Recital 229, Decision_act (EU) 1996/435

In forcesince 16 Jan 1996

Additional to the considerable capital outlay on the new plant investment, the new entrant would also be confronted by the need to sell approximately 50 000 tonnes of tissue products. This corresponds to about 7 % of current UK requirements. Given the entrenched position the merging parties would hold and the level of profits enjoyed on their branded products, it would be a very hazardous proposition to assume that the new entrant would be able to take successfully the required degree of market share from the incumbents.